Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Cholesterol Metabolite Contributes to Buildup of Atherosclerotic Plaques

By BiotechDaily International staff writers
Posted on 01 Jul 2014
A recent paper described the mechanism by which the cholesterol metabolite 27-hydroxycholesterol (27HC) contributes to the development of the fatty plaques that characterize atherosclerosis.

27HC is an abundant oxysterol metabolized by an enzyme encoded by the CYP7B1 (cytochrome P450, family 7, subfamily B, polypeptide 1) gene. This gene encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases, which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids, and other lipids. This enzyme likely plays a minor role in total bile acid synthesis, but may also be involved in the development of atherosclerosis, neurosteroid metabolism, and sex hormone synthesis.

Investigators at the University of Texas Southwestern Medical Center (Dallas, USA) used mouse and culture models to determine how 27HC modulated lipid metabolism. Results published in the June 2014 online edition of the journal Cell Metabolism revealed that in a mouse model (apoe−/−) where 27HC was elevated due to the genetically engineered deletion of CYP7B1, development of atherosclerosis was promoted without altering lipid status while estrogen-related atheroprotection was weakened.

27HC was found to upregulate proinflammatory genes and increase adhesion via the estrogen receptor in monocytes and macrophages. In endothelial cells, 27HC was also pro-adhesive via the estrogen receptor, and in contrast to estrogen, which inhibited NF-kappaB activation, 27HC stimulated NF-kappaB activation.

"When 27HC is present, estrogen's protective effects are only observed at very high levels of the hormone," said senior author Dr. Philip W. Shaul, professor of pediatrics at the University of Texas Southwestern Medical Center. "This result may explain why hormone therapy with estrogen does not provide cardiovascular benefit in women with preexisting atherosclerosis, in which 27HC is abundant in the vascular wall. Although statins have had a dramatic impact on cardiovascular health by lowering cholesterol, we still need complementary methods to combat atherosclerosis. Targeting 27HC, either by lowering the levels of this compound or by inhibiting its actions, could potentially provide a complementary approach to preventing vascular disease."

Related Links:

University of Texas Southwestern Medical Center



Channels

Drug Discovery

view channel
Image: Molecular model of the protein Saposin C (Photo courtesy of Wikimedia Commons).

Nanovesicles Kill Human Lung Cancer Cells in Culture and in a Mouse Xenograft Model

Nanovesicles assembled from the protein Saposin C (SapC) and the phospholipid dioleoylphosphatidylserine (DOPS) were shown to be potent inhibitors of lung cancer cells in culture and in a mouse xenograft model.... Read more

Biochemistry

view channel

Possible New Target Found for Treating Brain Inflammation

Scientists have identified an enzyme that produces a class of inflammatory lipid molecules in the brain. Abnormally high levels of these molecules appear to cause a rare inherited eurodegenerative disorder, and that disorder now may be treatable if researchers can develop suitable drug candidates that suppress this enzyme.... Read more

Lab Technologies

view channel
Image: The FLUOVIEW FVMPE-RS Gantry microscope (Photo courtesy of Olympus).

New Multiphoton Laser Scanning Microscope Configurations Expand Research Potential

Two new configurations of a state-of-the-art multiphoton laser scanning microscope extend the usefulness of the instrument for examining rapidly occurring biological events and for obtaining images from... Read more

Business

view channel

Roche Acquires Signature Diagnostics to Advance Translational Research

Roche (Basel, Switzerland) will advance translational research for next generation sequencing (NGS) diagnostics by leveraging the unique expertise of Signature Diagnostics AG (Potsdam, Germany) in biobanks and development of novel NGS diagnostic assays. Signature Diagnostics is a privately held translational oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.